WallStSmart

Insmed Inc (INSM)vsPrecigen Inc (PGEN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 13873% more annual revenue ($606.42M vs $4.34M). PGEN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

PGEN

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.3
Piotroski: 2/9Altman Z: -22.15

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

PGEN1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.4%8/10

19.4% revenue growth

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

PGEN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.36B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : PGEN

The strongest argument for PGEN centers on Revenue Growth. Revenue growth of 19.4% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : PGEN

The primary concerns for PGEN are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while PGEN is a growth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

PGEN is growing revenue faster at 19.4% — sustainability is the question.

PGEN generates stronger free cash flow (-29M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Precigen Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.

Want to dig deeper into these stocks?